Hixon Zuercher LLC Boosts Stock Holdings in Pfizer Inc. $PFE

Hixon Zuercher LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 3.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 83,649 shares of the biopharmaceutical company’s stock after buying an additional 2,866 shares during the quarter. Hixon Zuercher LLC’s holdings in Pfizer were worth $2,028,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently made changes to their positions in the company. GKV Capital Management Co. Inc. purchased a new stake in Pfizer in the 1st quarter worth about $27,000. Curio Wealth LLC boosted its holdings in Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 1,098 shares during the period. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter valued at $28,000. North Capital Inc. purchased a new stake in shares of Pfizer during the first quarter worth $28,000. Finally, Harbor Asset Planning Inc. purchased a new position in shares of Pfizer in the second quarter valued at $29,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $24.79 on Friday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $29.17. The company has a fifty day moving average of $24.87 and a 200-day moving average of $24.18. The company has a market capitalization of $140.92 billion, a P/E ratio of 13.18, a P/E/G ratio of 0.82 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the business posted $0.60 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s payout ratio is presently 91.49%.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Citigroup raised their target price on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Saturday. UBS Group reiterated a “neutral” rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Bank of America boosted their price target on shares of Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research report on Friday, October 3rd. Finally, Wall Street Zen downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Sunday, September 28th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $28.13.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.